Back | Next |
home / stock / nrsn / nrsn message board
Subject | By | Source | When |
---|---|---|---|
Wow! Finally moving. I mean ALS...Come on man! | frankyahoo | investorshub | 06/29/2022 12:57:13 PM |
Yup and now starting to get more investor interest | subslover | investorshub | 06/29/2022 12:55:11 PM |
Cool. Seeing a small spike premarket. $NRSN | frankyahoo | investorshub | 06/29/2022 12:47:36 PM |
NeuroSense Therapeutics reports completion of the in-life phase | subslover | investorshub | 06/29/2022 12:44:50 PM |
$NRSN | frankyahoo | investorshub | 06/27/2022 11:36:25 PM |
Exactly! Nice to meet you! | subslover | investorshub | 06/27/2022 10:15:21 PM |
$NRSN 2.42- why drop from | swampboots | investorshub | 06/27/2022 8:31:53 PM |
Great spike up today! Protect profits... especially in | $treet $inatra | investorshub | 06/27/2022 7:52:39 PM |
NeuroSense Therapeutics Reports Positive Results from Stage III | subslover | investorshub | 06/27/2022 12:56:28 PM |
$NRSN due for a run with the bouncing market | $treet $inatra | investorshub | 06/17/2022 7:55:01 PM |
Added more | heyitsmeagain | investorshub | 04/12/2022 6:23:27 PM |
Dunno what is but bought 25000 shares | heyitsmeagain | investorshub | 04/11/2022 1:53:41 PM |
Do what?.. It was down 30% yesterday morning. | 420man | investorshub | 03/23/2022 9:32:00 PM |
,,,,,,,MAKE SURE U FOLLOW ME | THEMASTERS_SON | investorshub | 03/23/2022 8:46:49 PM |
,,,,,,,BACK IN THIS $ONE TOMORROW | THEMASTERS_SON | investorshub | 03/23/2022 8:05:38 PM |
Momentum sma is above the ceiling! | HeilHiden | investorshub | 03/23/2022 7:32:20 PM |
Shares are thin up to 7.5! | HeilHiden | investorshub | 03/23/2022 7:27:43 PM |
Lock and load them! | HeilHiden | investorshub | 03/23/2022 7:19:09 PM |
Large MM buys 5.50+ I am very confident | HeilHiden | investorshub | 03/23/2022 7:10:21 PM |
$NRSN: Let's break that $8 | Sibware | investorshub | 03/23/2022 1:48:26 PM |
News, Short Squeeze, Breakout and More Instantly...
NeuroSense Therapeutics Ltd. Company Name:
NRSN Stock Symbol:
NASDAQ Market:
NeuroSense Therapeutics Ltd. Website:
NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression PR Newswire NeuroSense to submit the 12-month data to FDA to discuss path forward CAMBRIDGE, Mass. ...
NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug PR Newswire Disease progression was slowed by 36% (p=...
NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results PR Newswire Following positive 6-month clinical outcomes from phase 2b (PARADIGM) clinical trial, Company expects additional biomarker and 12-month clinical in the near term ...